Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
about
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian miceEvaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysFocus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.Monkey adrenal chromaffin cells express α6β4* nicotinic acetylcholine receptorsNicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function miceRole of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.The effect of cigarette smoke exposure on spinal cord injury in ratsPositional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxiaNicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseStriatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Targeting nicotinic receptors for Parkinson's disease therapy.Can nicotine be used medicinally in Parkinson's disease?Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsEffect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Mesenchymal stromal SB623 cell implantation mitigates nigrostriatal dopaminergic damage in a mouse model of Parkinson's disease.The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.The striatal cholinergic system in L-dopa-induced dyskinesias.
P2860
Q30450052-1CDE0FB1-BED2-4D4F-B750-84451D042013Q33790163-BF2CD153-7F6B-4925-82FF-0F506C9B2C61Q34112026-7E1890F7-05B1-4506-BF25-B243E49F0A99Q34186299-E5E83F23-C02F-4BD3-93D5-BAD508ABC0A3Q34793270-E100B883-CE06-4BF9-8C6F-DCDCC8602EF6Q35146483-A38BBE61-41B8-4402-8E12-FFE434AF9190Q35188119-8342AA21-0A7D-4263-8F9B-5341B3A9BFA4Q35264378-270A0661-875D-4543-A059-DF89422886A8Q35533526-68D2015D-B634-4549-B492-6BEA8ED8D7EDQ35690145-0D0925E3-0210-48A3-8C91-CFCCBF5537BBQ35776860-6ED26F24-53D1-408C-9C95-0F79678E71AFQ36469995-BAE19DDD-CA20-4748-BEED-9D10EB8D2509Q36936920-08F48315-2B0D-4795-83A9-BF6FDC42D511Q36936930-E30E0864-B55F-47BF-B696-C7B76092A0A8Q36968326-04AC9163-6591-4442-9375-A128B46E1183Q37132142-BC9030A1-360A-4503-8E58-BC46BD0EE73CQ37154555-84456902-CD1A-45C9-BA63-395F3EADCB8FQ37193201-86ACF1E4-AD39-4972-82D1-EB4BA6737C70Q37209730-5043DDFE-FEAC-420E-B8CB-C624E46362B0Q37597274-CCC0A241-4D33-461E-8723-628AF98440B1Q37708588-8F03DD4B-90EA-454E-8DC0-51738313FB23Q37916643-57F02C40-6D37-4104-9C44-314F8B3C9E5EQ37960523-F101F85C-8C0C-444D-BB51-BB8D28D82C47Q38156760-FE589CAE-D355-48E0-82F7-2F05BB3B2979Q38186596-AE00F4A9-E78A-4E71-A004-AA9017FF0B1FQ38209988-A88DE928-29AD-4185-9ED6-FE9B861CAB58Q38629277-D966DC85-7DB6-4F06-B31A-AA05F87A59DCQ40461839-0A2EEBE0-7454-41CE-BA2C-7132088FFF02Q42640556-391C56F6-16C4-4E53-93A5-8E9841C98698Q42676936-98F9C1F9-307A-42FE-8302-1A9F750BC3B1Q45961748-F29369F5-E537-4510-A40B-6B68E75D391CQ46552807-FF58D180-B89A-4EC8-B08E-4D1A9F1ACC93Q52680310-2D0B7340-8CF0-4D40-8FE0-FECAB86A5C05
P2860
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@ast
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@en
type
label
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@ast
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@en
prefLabel
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@ast
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@en
P2093
P2860
P1433
P1476
Nicotinic receptor agonists de ...... ly lesioned parkinsonian rats.
@en
P2093
Carla Campos
F Ivy Carroll
Luping Z Huang
Maryka Quik
P2860
P304
P356
10.1016/J.NEUROPHARM.2010.12.032
P577
2011-01-11T00:00:00Z